Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 35Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 16Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × gastrin immunogen × Clear all
NCT00020787 2020-08-03

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Jonsson Comprehensive Cancer Center

Phase 3 Completed
8 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT02521649 2015-08-13

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Cancer Advances Inc.

Phase 2 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02518529 2015-08-10

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

Cancer Advances Inc.

Phase 2 Completed
41 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡